Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2020-01-08 Regulatory Filings
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated January 8, 2020, announcing positive results from a clinical trial regarding the use of the Cellvizio platform for pancreatic cystic lesions. It details study outcomes, quotes management and a key physician, and includes standard boilerplate information about the company and forward-looking statements. This format—an announcement of positive clinical/study results, often tied to a publication in a journal, intended for investors and the public—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/product news. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Update (CAP), the most appropriate classification for a press release announcing key operational/clinical achievements is Earnings Release (ER), as these often accompany or substitute for formal quarterly updates, or Regulatory Filings (RNS) as a general announcement. Given the focus on clinical results and the structure of a press release, ER is often used for such announcements, but RNS is the general fallback. However, since this is a major announcement of positive results that impacts the company's outlook, and it is not explicitly an earnings report, it fits best under the general category for significant corporate announcements that aren't strictly financial reporting or specific regulatory forms. Given the options, and recognizing this is a news announcement rather than a formal financial report, RNS (Regulatory Filings/General Announcement) is the safest fit, although ER is plausible if this was released around an earnings period. Since it is a press release announcing a publication, RNS is the most accurate general classification for non-standard, non-financial regulatory news.
2020-01-08 French
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils et déclaration d'intention (article L. 233-7 du code de commerce)" and details that Johnson & Johnson Innovation – JJDC, Inc. crossed ownership thresholds (5%, 10%, 15%) in MAUNA KEA TECHNOLOGIES following a capital increase. This type of mandatory filing in France, reporting changes in significant share ownership and stating future intentions, directly corresponds to the definition of a Major Shareholding Notification. The code for this is MRQ.
2019-12-23 French
Inside Information / Other news releases
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing a strategic equity investment of €7.5 million from Johnson & Johnson Innovation. It details the terms of the share subscription, the intended use of proceeds, and the expected closing date. This type of announcement, concerning fundraising, capital structure changes, and significant financing activities, directly aligns with the definition of a Capital/Financing Update. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER) as it focuses on a specific financing event rather than comprehensive periodic financial results. It is a specific corporate action announcement, making 'CAP' the most appropriate classification over the general 'RNS' fallback.
2019-12-16 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated December 16, 2019, announcing a strategic investment of 7.5 million Euros from Johnson & Johnson Innovation (JJDC) in exchange for new ordinary shares. This transaction involves the issuance of new capital and changes to the company's financing structure. Key terms like 'investissement stratégique', 'acquisition de ... actions ordinaires nouvelles', 'augmentation de capital', and 'produit net de l'émission' strongly indicate a corporate financing event. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the filing of a universal registration document (document d'enregistrement universel) with the AMF, the primary purpose of this text is the announcement of the capital raise itself, not the filing of the full annual report (10-K) or an interim report (IR).
2019-12-16 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated November 7, 2019, announcing that Mauna Kea Technologies is part of a consortium awarded a €5.4 million grant for a research program related to molecular imaging and pulmonary diseases. This announcement details a strategic partnership, R&D focus, and potential future applications, but it is not a formal regulatory financial filing (like 10-K, IR, or ER). It is an announcement concerning company activities, partnerships, and strategic direction, which fits best under the general category of Investor Relations or a specific announcement that doesn't fit the other defined categories. Since it is a general announcement about company news and strategy, and not a specific financial report, management discussion, or insider trade, it most closely aligns with a general regulatory announcement or investor news item. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-financial, non-management-change news that is being publicly disclosed, although 'Investor Presentation' (IP) or 'Management Reports' (MDA) might seem related to strategy, this is a press release about a grant award, not a presentation or a management discussion of past results. RNS serves as the best general regulatory/public disclosure category here.
2019-11-07 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated November 7, 2019, announcing that Mauna Kea Technologies is part of a Dutch consortium that received a €5.4 million grant from the NWO for molecular imaging research related to pulmonary diseases. This type of announcement, detailing participation in a research grant, strategic partnership, or general corporate development news that is not a formal financial report (like 10-K, IR, ER) or a specific regulatory filing (like DIRS, DIV), typically falls under general corporate news or investor relations updates. Since it is an announcement of a strategic development rather than a formal financial filing, and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it is best classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially Investor Presentation (IP) if it were a presentation, but here it reads like a news release. Given the options, RNS serves as the most appropriate fallback for a significant, non-financial, non-management change announcement.
2019-11-07 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.